Last reviewed · How we verify

Amlodipine-FA tablet,high dose group — Competitive Intelligence Brief

Amlodipine-FA tablet,high dose group (Amlodipine-FA tablet,high dose group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

phase 2 Calcium channel blocker L-type calcium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine-FA tablet,high dose group (Amlodipine-FA tablet,high dose group) — Shenzhen Ausa Pharmed Co.,Ltd. Amlodipine-FA tablet works by inhibiting the L-type calcium channels in smooth muscle cells, leading to vasodilation and reduced blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amlodipine-FA tablet,high dose group TARGET Amlodipine-FA tablet,high dose group Shenzhen Ausa Pharmed Co.,Ltd phase 2 Calcium channel blocker L-type calcium channels
Nicardipine , Esmolol Nicardipine , Esmolol Nanjing Medical University marketed Calcium channel blocker + Beta-1 selective adrenergic antagonist combination L-type calcium channels; Beta-1 adrenergic receptor
losartan/amlodpine losartan/amlodpine University of Pavia marketed Angiotensin II receptor blocker (ARB) / Calcium channel blocker (CCB) Angiotensin II receptors (AT1) and L-type calcium channels
Norvasc Amlodipine Besylate Pfizer Inc. marketed Dihydropyridine calcium channel antagonist L-type calcium channels
flunarizine and/or pregabalin flunarizine and/or pregabalin Taipei Veterans General Hospital, Taiwan marketed ["Calcium Channel Blocker", "Anticonvulsant"] ["L-type calcium channels", "alpha2-delta subunit of voltage-gated calcium channels"]
Amlodipine Besylate / Benazepril Hydrochloride Amlodipine Besylate / Benazepril Hydrochloride Dr. Reddy's Laboratories Limited marketed Calcium channel blocker / ACE inhibitor combination L-type calcium channels; Angiotensin-converting enzyme (ACE)
irbesartan, amlodipine and hydrochlorothiazide irbesartan, amlodipine and hydrochlorothiazide Assistance Publique - Hôpitaux de Paris marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

  1. Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
  2. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
  3. Ain Shams University · 1 drug in this class
  4. Bioprojet · 1 drug in this class
  5. Bristol-Myers Squibb · 1 drug in this class
  6. GlaxoSmithKline · 1 drug in this class
  7. Handok Inc. · 1 drug in this class
  8. Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
  9. Hospital de Clinicas de Porto Alegre · 1 drug in this class
  10. Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine-FA tablet,high dose group — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-fa-tablet-high-dose-group. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: